Alphamab Oncology 2024 SR
The report highlights Alphamab Oncology's commitment to innovative cancer treatments, featuring the world's first subcutaneously injectable PD-L1 inhibitor, ENWEIDA. In 2024, the company achieved significant R&D milestones, including breakthrough therapy designations and successful clinical trials for its ADC and bispecific antibody pipeline. The company demonstrated strong ESG performance by reducing greenhouse gas emission intensity by 6.96% and energy consumption intensity by 14.40% compared to 2023. Furthermore, Alphamab Oncology emphasized responsible management, intellectual property protection, and community engagement through patient assistance programs and science education initiatives.
Company: Alphamab Oncology
Sector: Health Care
Country: China
Year: 2024
Type: SR
Pages: 39
Alphamab Oncology
ESG Report
The report highlights Alphamab Oncology's commitment to innovative cancer treatments, featuring the world's first subcutaneously injectable PD-L1 inhibitor, ENWEIDA. In 2024, the company achieved significant R&D milestones, including breakthrough therapy designations and successful clinical trials for its ADC and bispecific antibody pipeline. The company demonstrated strong ESG performance by reducing greenhouse gas emission intensity by 6.96% and energy consumption intensity by 14.40% compared to 2023. Furthermore, Alphamab Oncology emphasized responsible management, intellectual property protection, and community engagement through patient assistance programs and science education initiatives.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees